Rallybio Corporation (RLYB) announced an update on their ongoing clinical study.
Idaho’s 2026 Legislature is beginning. Pending regulations will be finalized, new laws debated, and spending on old laws ...
Johnson & Johnson today announced new longer follow-up results from the investigational Phase 1b/2 OrigAMI-1 study evaluating amivantamab-vmjw, a bispecific antibody targeting epidermal growth factor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback